Key result
Prasugrel was approved by the FDA for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Why the study?
Does prasugrel reduce thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does prasugrel reduce thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
The FDA approved prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
The Food and Drug Administration (FDA) approved prasugrel on July 10, 2009. Developed by Eli Lilly and Daiichi Sankyo, prasugrel is a thienopyridine that inhibits platelet aggregation. It was approved for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina or myocardial infarction) who undergo percutaneous coronary intervention (PCI). The FDA grappled with a number of complex issues during the review process,1 and the application was presented to the Cardiovascular and Renal Drugs Advisory Committee on February 3, 2009.2 The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial . . .
No takes yet. Share an insight, caveat, or question.
Ellis F. Unger (2009) conducted a review in Acute coronary syndrome undergoing percutaneous coronary intervention. Prasugrel was evaluated on Thrombotic cardiovascular events. Prasugrel was approved by the FDA for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: